US EditionLow-dose olanzapine approach ‘new standard of care’ for chemotherapy nausea and vomiting
Summary by medwirenews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Low-dose olanzapine approach ‘new standard of care’ for chemotherapy nausea and vomiting
By Lynda Williams, medwireNews ReportermedwireNews: Low-dose olanzapine significantly protects against nausea and vomiting compared with placebo for women with breast cancer receiving anthracycline plus cyclophosphamide chemotherapy, show phase 3 trial findings published in The Lancet Oncology.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
